A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)

NAEnrolling by invitationINTERVENTIONAL
Enrollment

17,400

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

December 31, 2037

Study Completion Date

December 31, 2037

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

Prostate cancer screening

Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.

Trial Locations (2)

Unknown

Helsinki University and Helsinki University Hospital, Helsinki

University of Tampere, Tampere

All Listed Sponsors
collaborator

Helsinki University Central Hospital

OTHER

collaborator

Tampere University Hospital

OTHER

collaborator

Finnish Cancer Registry, Finland

UNKNOWN

collaborator

University of Turku

OTHER

collaborator

Lund University

OTHER

collaborator

Fimlab Laboratories, Finland

UNKNOWN

collaborator

Laboratory HUSLAB, Finland

UNKNOWN

collaborator

University of Helsinki

OTHER

collaborator

Hospital District of Helsinki and Uusimaa

OTHER

collaborator

Clinical Research Institute HUCH Ltd

OTHER

lead

Tampere University

OTHER